EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance

Sophie Mueller, Isabel Grote, Stephan Bartels, Leonie Kandt, Henriette Christgen, Ulrich Lehmann, Oleg Gluz, Monika Graeser, Ron Kates, Nadia Harbeck, Hans Kreipe, Matthias Christgen

Modern Pathology · 2023-04 · 36 (4) · 100100

DOI: 10.1016/j.modpat.2023.100100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023-04. Verfasst von Sophie Mueller und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TP53 mutation is associated with primary endocrine resistance in luminal breast cancer (BC). Nuclear accumulation of p53, as determined by immunohistochemistry (IHC), is a surrogate marker for TP53 mutation. The immunohistochemical p53 index that defines a p53-positive status is not well established. This study determined the optimal p53 index cutoff to identify luminal BCs harboring TP53 mutations. In total, 364 luminal BCs from the West German Study Group ADAPT trial (NCT01779206) were analyzed for TP53 mutations by next-generation sequencing and for p53 expression by IHC (DO-7 antibody). P53 indices were determined by automated image analysis. All tumors were from patients treated with short-term preoperative endocrine therapy (pET; tamoxifen or aromatase inhibitor) before tumor resection. IHC evaluation included needle biopsies before therapy (baseline) and resections specimens after therapy (post-pET). Optimal p53 index cutoffs were defined with Youden statistics. TP53 mutations were detected in 16.3% of BC cases. The median p53 indices were significantly higher in TP53-mutated BCs compared to BCs harboring wild-type TP53 (baseline: 47.0% vs 6.4%, P 2-fold more common in pET nonresponders compared to pET responders (baseline: 37/162, 22.8% vs 18/162, 11.1%, P = .007; post-pET: 36/179, 20.1% vs 16/179, 8.9%, P = .004). In summary, IHC for p53 identifies TP53-mutated luminal BCs with high specificity and accuracy. Optimal cutoffs are ≥35% and ≥25% for treatment-naïve and endocrine-pretreated patients, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleTumor Suppressor Protein p53Mutation

Stichwörter der Autor:innen

endocrine resistanceimmunohistochemistrymolecular subtyping

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • West German Study Group, Moenchengladbach, Germany; Ev. Bethesda Hospital, Moenchengladbach, Germany; Women's Clinic and Breast Center, University Clinics Cologne, Cologne, Germany.
  • West German Study Group, Moenchengladbach, Germany; Ev. Bethesda Hospital, Moenchengladbach, Germany; Department of Gynecology, University Medical Center Hamburg, Hamburg, Germany.
  • West German Study Group, Moenchengladbach, Germany.
  • West German Study Group, Moenchengladbach, Germany; Department of OB&GYN and CCC Munich, Breast Center, LMU University Hospital, Munich, Germany.
  • Institute of Pathology, Hannover Medical School, Hannover, Germany. Electronic address: Christgen.Matthias@MH-Hannover.de.

Förderung

  • Deutsche Krebshilfe

Zitieren

APA

Mueller, S., Grote, I., Bartels, S., Kandt, L., Christgen, H., Lehmann, U., Gluz, O., Graeser, M., Kates, R., Harbeck, N., Kreipe, H., & Christgen, M. (2023). p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance. Modern Pathology, 36(4), 100100. https://doi.org/10.1016/j.modpat.2023.100100

Vancouver

Mueller S, Grote I, Bartels S, Kandt L, Christgen H, Lehmann U, et al. p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance. Modern Pathology. 2023;36(4):100100. doi:10.1016/j.modpat.2023.100100

BibTeX
@article{Mueller2023,
  author = {Mueller, Sophie and Grote, Isabel and Bartels, Stephan and Kandt, Leonie and Christgen, Henriette and Lehmann, Ulrich and Gluz, Oleg and Graeser, Monika and Kates, Ron and Harbeck, Nadia and Kreipe, Hans and Christgen, Matthias},
  title = {p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance},
  journal = {Modern Pathology},
  year = {2023},
  volume = {36},
  number = {4},
  pages = {100100},
  doi = {10.1016/j.modpat.2023.100100}
}
Kostenlos starten →